Business
Wearables partnership
Wearables partnership.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5224Q Cambridge Cognition Holdings PLC 01 March 2016 \n\n1 March 2016\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\n \nUK companies Cambridge Cognition and Ctrl Group partner to develop first wearables for real-time cognitive health monitoring\n \nCambridge Cognition Holdings plc, (AIM: COG), which specialises in cognitive assessment technologies including those enabling the early detection of Alzheimer's disease, announces a new partnership with London based design and research agency Ctrl Group to produce novel digital health applications for new markets with prototype products expected in the second half of 2016.\n \nMental ill health is the world's largest cause of disability and economic loss. In the UK alone, one in four adults experience at least one diagnosable mental health problem each year1. With an estimated half a billion people affected worldwide, the cost to global economies is on course to exceed $6 trillion per annum by 20302.\nCommon mental health disorders such as dementia, depression and anxiety are characterised by symptoms that can fluctuate regularly, which until now has created difficulties for researchers and healthcare professionals as infrequent assessments in controlled settings are unable to reflect a patient's health between visits and in everyday life.\nBy engaging with individuals through wearable and smart devices the new technology being developed will provide a richer and more natural profile of mental health to improve the understanding, diagnosis and treatment of cognitive disorders; helping people to lead fuller, more active lives and dramatically reduce global healthcare costs.\nUnder the terms of the partnership, digital health products are being designed and developed enabling near-user cognitive testing on wearable and smart devices. More meaningful cognitive data will enable healthcare practitioners to detect mental health risk factors earlier, reduce the likelihood of relapse and, by tracking daily activity, help individuals to better understand and manage their cognitive health in a way that products such as Fitbit® have for physical health. For pharmaceutical companies, understanding the real world impact of interventions will support clinical trials of drug development candidates and marketed treatments for chroni...